-
First Cork patient enrolled onto the DICE trial
@cancertrials_ie: phase 2 study of#denosumab with#enzalutamide in advanced#ProstateCancer with bone metastasis. Ask your oncologist about potential suitable trials recruiting in Ireland#Clinicaltrial#cancerpatients -
Maha Hussain shows
#Enzalutamide activity in non metastatic CRPC.#GU18pic.twitter.com/yEt4wv1KZJ
-
Article Online: Optimal
#sequencing of#enzalutamide and#abiraterone acetate plus#prednisone in metastatic castration-resistant#prostatecancer: a randomised, open-label, phase 2 crossover trialpic.twitter.com/upPvqYbzjm
Prikaži ovu nit -
The
#FDA has approved#enzalutamide (Xtandi®) for patients with metastatic castration-sensitive#ProstateCancer (#mCSPC), based on the ARCHES trial led by@AarmstrongDuke of@DukeCancer: https://i3health.us/news/enzalutamide-approved-in-metastatic-castration-sensitive-prostate-cancer …#oncology#urology#CancerNews#pcsm -
Dr. Kim Chi phase II of cabazitaxel (CAB) vs
#abiraterone or#enzalutamide in poor-risk#mCRPC showed improved CBR with CAB and prolonged SD, trend to OS benefit with first-line CAB@ASCO@ASCOpost#ASCO19pic.twitter.com/B3ORrhTjls
-
#Darolutamide targets#Enzalutamide resistant#CRPC -> Towards Precision#Urology#Oncology#ProstateCancer#PCSM https://buff.ly/2knG3GO -
Dr. Morris: simply not that much more anticancer activity w/addition of
#enzalutamide to#abiraterone vs enza alone in@ALLIANCE_org phase III trial in#mCRPC. More AEs with combination#asco19@ASCOPostpic.twitter.com/yynR2CA17u
-
Dr.Antonarakis:full length Androgen receptor neg CTCs may predict response to
#abiraterone &#enzalutamide#prostatecancer#GU17pic.twitter.com/79Hlqvma7T
-
In head to head comparison
#enzalutamide w better PSA resp cw#abiraterone but no difference in PFS in#CRPC#ASCO17pic.twitter.com/VDDbA5XaCg
-
.Kayla Gu, MS1
@UCLAHealth speaks to the@UofCalifornia Board of Regents on the behalf of@UAEM urging@UCLA to drop the patent claim in India on#enzalutamide/#Xtandi that would bar affordable access to a lifesaving prostate cancer drugpic.twitter.com/DwitMy4YUD
-
BREAKING NEWS!
@FDArecalls approves#enzalutamide for the treatment of non-metastatic castration-resistant#prostatecancer (non-metastatic CRPC) https://www.businesswire.com/news/home/20180713005429/en/U.S.-FDA-Approves-XTANDI%C2%AE-enzalutamide-Treatment-Men#.W0j70uQkVh4.twitter … -
Karim Fizazi presents data on
#darolutamide in M0 CRPC - with MFS benefit similar to#enzalutamide and#apalutamide. Low fatigue. Now there are 3 drugs. Will the blood brain barrier be the great separator?#GU19@ASCO@PCF_Sciencepic.twitter.com/gNwzmbJpQ8
-
Our recent ASCO abstract describing the ENZADA trial for patients with newly diagnosed metastatic prostate cancer. This trial is only available at
#levinecancerinstitute and is testing the combination of ADT + docetaxel +#enzalutamide. https://meetinglibrary.asco.org/record/165367/abstract … -
#enzalutamide#ProstateCancer#crpc@Uroweb@SIU_Italia@4prost8health@PCFnews Outstanding results of Enzalutamide in M0 castration resistant prostate cancer!pic.twitter.com/1einGYLXVG
-
#GU19 Genomic drivers of poor prognosis and enzalutamide resistance in mCRPC, William S. Chen of@UCSFCancer . RB1 loss and Wnt/CTNNB1 associated with shorter survival and Wnt/beta-catenin pathway is a predictive of#Enzalutamide resistance. pic.twitter.com/jXmzynsc5EOvo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
-
Fascinating work on interaction between gut
#microbiome mileu and androgen axis-targeted therapies (#bicalutamide#enzalutamide#abiraterone) -- bidirectional relationship with implications on PCa response to#immunotherapy@sfanoslabhttps://twitter.com/sfanoslab/status/1016696590369685505 … -
#ENZAMET trial:#enzalutamide in hormone sensitive metastasic#ProstateCancer : benefit in overall survival, although this benefitnis not observed in patients treated with docetaxel. More follow-up is needed.#ASCO19pic.twitter.com/ub46V6rTvk
-
Dorff - 42% of ARV7+
#prostatecancer patients treated with#enzalutamide had response#ASCO17pic.twitter.com/3BirXYnvFg
-
#GU18 high-risk non-metastatic castrate-refractory#ProstateCancer : PROSPER vs SPARTAN (#enzalutamide vs#apalutamide ) - you decide!pic.twitter.com/5e4w3PJU3f
-
BREAKING NEWS! FDA approves
#enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant#prostatecancer (non-metastatic CRPC). PCF funded the early research to synthesize this drug. Read more: https://www.pcf.org/news/breaking-news-fda-approves-enzalutamide-xtandi-for-non-metastatic-castration-resistant-prostate-cancer/ …pic.twitter.com/LWP1RgYdjE
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.